Acrivon Therapeutics is proudly showcasing its groundbreaking ACR-368 OncoSignature test at the highly anticipated AACR-NCI-EORTC International Conference, set to take place on September 19, 2023. This innovative test is currently being utilized in a Phase 2 study aimed at revolutionizing the treatment of patients by accurately predicting their sensitivity to the CHK1/2 inhibitor ACR-368.
The ongoing study focuses on patients diagnosed with ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma. By employing the OncoSignature test, a cutting-edge proteomic companion diagnostic, medical professionals can now identify those patients who are most likely to benefit from ACR-368 monotherapy.
Patients who receive a positive OncoSignature test result will be enrolled in the Phase 2 study, which will meticulously evaluate the efficacy of ACR-368 as a standalone treatment. Utilizing the Simon two-stage design, this study aims to provide valuable insights into the potential of ACR-368 monotherapy for OncoSignature-positive patients. These patients will be administered ACR-368 at the recommended Phase 2 dose.
One of the most remarkable aspects of the OncoSignature test is its ability to predict drug sensitivity across various tumor types. This groundbreaking diagnostic tool is designed to revolutionize the field of personalized medicine by accurately identifying patients who are most likely to respond positively to ACR-368 monotherapy, regardless of their specific tumor type.
Acrivon Therapeutics, Inc. Common Stock
ACRV
Updated on: 27/09/2023
Financial Health
Neutral
Debt to equity ratio:
Price to earnings ratio:
Price to book ratio:
DCF:
ROE:
ACRV Stock: Stable Performance and Positive Earnings Growth in the Health Technology Sector
ACRV stock, belonging to the Health Technology sector and the Pharmaceuticals: Major industry, had a relatively stable performance on September 19, 2023. The stock opened at the same price as the previous close, $10.06, and traded in a range of $9.74 to $10.06 throughout the day. The volume was relatively low at 176, compared to the average volume of 22,296 over the past three months.
With a market capitalization of $232.9 million, ACRV is considered a small-cap stock. The company’s earnings growth last year was negative, with a decline of 82.59%. However, this year, the company has shown positive earnings growth of 65.92%. Unfortunately, there is no data available regarding the projected earnings growth for the next five years.
ACRV’s revenue growth for the last year is not provided, so it is unclear how the company has performed in terms of generating revenue. The P/E ratio is not mentioned, and there is no information on the price/sales ratio. However, the price/book ratio is 1.36, which suggests that the stock may be undervalued compared to its book value.
It is worth noting that there is no data available on ACRV’s competitors, so it is difficult to assess the company’s market position and competitive advantage. The next reporting date is scheduled for November 29, 2023, which will provide investors with more information about the company’s financial performance.
The EPS forecast for this quarter is -$0.69, indicating that the company is expected to report a loss. In the previous year, ACRV reported zero annual revenue and a net loss of $31.2 million. Unfortunately, the net profit margin is not provided, so it is unclear how profitable the company is relative to its revenue.
Overall, ACRV’s stock performance on September 19, 2023, was relatively stable, with no significant changes in price. The company has shown positive earnings growth this year, but its past performance indicates challenges in generating revenue and profitability. Investors will have to wait until the next reporting date to gain more insights into the company’s financial health and prospects.
ACRV Stock Shows Promising Performance on September 19, 2023: Analysts Recommend Buying Acrivon Therapeutics Inc
ACRV stock, belonging to Acrivon Therapeutics Inc, has shown a promising performance on September 19, 2023, based on the information provided by CNN Money. The stock has gained the attention of 7 analysts who have offered 12-month price forecasts for ACRV. The median target price stands at $25.00, with the highest estimate at $26.00 and the lowest estimate at $17.00. This indicates a potential increase of 153.81% from the last recorded price of $9.85.
The consensus among 8 polled investment analysts is to buy stock in Acrivon Therapeutics Inc. This rating has remained unchanged since September, indicating a consistent belief in the company’s growth prospects. Investors seem to have confidence in the future performance of ACRV, considering the positive sentiment expressed by analysts.
It is important to note that Acrivon Therapeutics Inc is still in the current quarter, with earnings per share standing at -$0.69 and sales at $0.00. The company is expected to report its financial results on November 29. These figures suggest that ACRV is currently in a growth phase, with potential for improvement in the coming months.
Investors should consider the positive outlook provided by analysts and the consensus to buy ACRV stock. The median target price of $25.00 indicates a substantial upside potential, making Acrivon Therapeutics Inc an attractive investment opportunity. However, it is essential to conduct further research and analysis before making any investment decisions, as stock market performance can be unpredictable.
Overall, ACRV stock has shown promising signs on September 19, 2023. The positive sentiment from analysts and the consensus to buy the stock, along with the projected increase in target price, indicate a favorable outlook for Acrivon Therapeutics Inc. Investors should closely monitor the upcoming financial results to gain a clearer understanding of the company’s performance and potential for growth.
Discussion about this post